Xin Lang Cai Jing·2025-10-31 06:07Core Viewpoint - WuXi AppTec is a leading global pharmaceutical R&D service platform, excelling in revenue and net profit within the industry, showcasing strong financial performance and growth potential [1][2][6]. Financial Performance - For Q3 2025, WuXi AppTec reported revenue of 32.857 billion yuan, ranking first among 29 companies in the industry, significantly surpassing the second-place company, Kanglong Chemical, which had revenue of 10.086 billion yuan [2]. - The net profit for the same period was 12.206 billion yuan, also leading the industry, with the second-place company, Tigermed, reporting a net profit of 1.092 billion yuan [2]. Financial Ratios - As of Q3 2025, WuXi AppTec's debt-to-asset ratio was 24.45%, lower than the industry average of 22.79%, indicating strong solvency [3]. - The gross profit margin for the same period was 46.62%, higher than the industry average of 37.70%, reflecting robust profitability [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 16.39% to 274,100, while the average number of circulating A-shares held per shareholder decreased by 14.49% to 9,024.76 [5]. Business Growth and Outlook - WuXi AppTec's revenue growth is attributed to a focus on CRDMO business, optimization of production processes, and operational efficiency, with a significant increase in orders on hand, totaling 59.88 billion yuan, up 41.2% year-on-year [6]. - The chemical business revenue for the first three quarters was 25.978 billion yuan, a year-on-year increase of 29.28%, while TIDES business revenue reached 7.84 billion yuan, growing by 121.1% [6]. - Revenue projections for 2025 to 2027 are 44.139 billion yuan, 49.219 billion yuan, and 56.818 billion yuan, respectively, with net profits expected to be 17.773 billion yuan, 17.997 billion yuan, and 19.035 billion yuan [6].